FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

被引：0
|
作者：
Moore, K. N. [1 ]
Vergote, I. [2 ]
Oaknin, A. [3 ]
Colombo, N. [4 ]
Banerjee, S. [5 ]
Oza, A. M. [6 ]
Pautier, P. [7 ]
Kelly, C. M. [8 ]
Malek, K. [9 ]
Birrer, M. J. [10 ]
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Obstet & Gynecol, Oklahoma City, OK USA
[2] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[4] Ist Europeo Oncol, Dept Gynecol Oncol, Milan, Italy
[5] Royal Marsden, Gynaecol Unit, London, England
[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[7] Gustave Roussy Inst Cancerol, Med Oncol, Villejuif, France
[8] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland
[9] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[10] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
991TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRa-positive, platinum-resistant ovarian cancer
    Konecny, Gottfried
    Moore, Kathleen
    Lebreton, Coriolan
    Weroha, Saravut
    Romeo Marin, Margarita
    McAvan, Lucy
    Colombo, Nicoletta
    O'Malley, David
    Coffman, Lan
    Roszak, Andrzej
    Shapira-Frommer, Ronnie
    Lalisang, Roy
    Cibula, David
    Barquin, Arantzazu
    Glasspool, Rosalind
    Stec, James
    Li, Lingling
    Method, Michael
    Hardy-Bessard, Anne Claire
    Van Gorp, Toon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S11 - S12
  • [42] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
    Matulonis, Ursula A.
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Romeo, Marga
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Method, Michael W.
    Esteves, Brooke
    Coleman, Robert L.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer
    Smit, W. M.
    Sufliarsky, J.
    Werner, T. L.
    Dizon, D.
    Wagnerova, M.
    Hirte, H. W.
    Delaney, R.
    Li, J.
    Weber, D.
    Schellens, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    O'Malley, David M.
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar M.
    Gilbert, Lucy
    Vergote, Ignace
    Martin, Lainie P.
    Mantia-Smaldone, Gina M.
    Gonzalez Martin, Antonio
    Bratos, Raquel
    Penson, Richard T.
    Malek, Karim
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 379 - 385
  • [45] GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
    O'Malley, David M.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Diver, Elisabeth
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Single-arm phase II trial of carboplatin and mirvetuximab soravtansine as neoadjuvant chemotherapy (NACT) for advanced-stage ovarian, fallopian tube or primary peritoneal cancer (EOC) who are folate receptor α positive (NCT04606914)
    Kako, Tavonna
    Dholakia, Jhalak
    Leath, Charles
    Arend, Rebecca
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S281 - S281
  • [47] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2022, 126 : 1695 - 1703
  • [49] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Roque, Dana M.
    Siegel, Eric R.
    Buza, Natalia
    Bellone, Stefania
    Silasi, Dan-Arin
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Rao, Gautam G.
    Reader, Jocelyn C.
    Hui, Pei
    Tymon-Rosario, Joan R.
    Harold, Justin
    Mauricio, Dennis
    Zeybek, Burak
    Menderes, Gulden
    Altwerger, Gary
    Ratner, Elena
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2022, 126 (12) : 1695 - 1703
  • [50] Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
    Borghaei, Hossein
    O'Malley, David M.
    Seward, Shelly Marie
    Bauer, Todd Michael
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Michenzie, Mary F.
    Kirby, Maurice William
    Chandorkar, Gurudatt
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345